ClinicalTrials.gg
RecruitingNCT06299852Updated Mar 8, 2024

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

An interventional study of Trastuzumab emtansine in HER2-positive Metastatic Breast Cancer and Oligometastatic Disease, sponsored by N.N. Petrov National Medical Research Center of Oncology. Recruiting at 1 site in Russian Federation. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by N.N. Petrov National Medical Research Center of Oncology · Not applicable, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 7 months after the study started (first participant enrolled Jul 2022, registered Feb 2024).
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Planned enrollment
36th of 56
58 · median 103
Started
2022
with 1 other
No phase
Only one
of the 56
Primary completion
2025-09
later than 4 of 15 live
Registered
50th of 56
by date

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 36th largest by planned enrollment, is one of 2 that started in 2022, is the only one with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 50th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who received treatment with trastuzumab-emtansine and had a history of SRT.

The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT followed by the administration of trastuzumab emtansine 24 hours after the SRT.

The combined effect of stereotactic radiation therapy on a metastatic lesion followed by anti-HER2 therapy in the 2nd line - trastuzumab emtansine, remains unexplored. This study plans to evaluate the effectiveness of combining systemic therapy and local control methods (SRT) in patients with oligometastatic HER2-positive breast cancer. It will be the first time the efficacy and toxic profile of this new combined treatment method in this patient population will be studied. This basket trial evaluates trastuzumab emtansine for oligo-metastatic breast cancer with the aim of inducing deep responses, long-lasting disease remissions, and potentially cure.

Read the detailed description

This study involves two non-randomized groups of patients: the observation group and the comparison group.

The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who were treated with trastuzumab-emtansine and had a history of SRT. The dynamics of the process will be evaluated retrospectively using CT and MRI data according to RECIST 1.1 criteria. The main statistical indicators will be calculated based on the patients' medical documentation.

The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT for up to 2 cycles, depending on the location of the irradiated focus, followed by administration of trastuzumab emtansine 3.6 mcg/kg once every 3 weeks, up to 4 total cycles. Trastuzumab emtansine therapy will be initiated 24 hours after the end of the course of SRT. Tumor foci will be assessed according to RECIST 1.1 criteria.

Objective response, general condition, and adverse events will be evaluated before, during, and after treatment.

Patients will be stratified by age, location of metastatic foci, and treatment. Outpatient patient records, medical histories, clinical and laboratory examination data, morphological examination data, CT findings, MRI findings will be used as sources of information for analyzing the results of diagnosis and treatment.

03

Conditions studied

  • HER2-positive Metastatic Breast Cancer
  • Oligometastatic Disease

Browse trials for

Keywords

  • HER2-positive
  • Breast cancer
  • Oligometastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be at least 18 years of age and able to give written and comply with study procedures;
  2. Clinical diagnosis: breast cancer, form;
  3. Oligo-metastatic disease as determined by standard of care diagnostics, limited to 5 total individual distant metastases, either in one organ or in 2-3 organ systems. Clustered lymph nodes that can be irradiated with curative intent in a single field are defined as single lesion;
  4. Possibility of complete elimination of all foci;
  5. expression level of 3+ points according to immunohistochemical analysis (IHC) and/or degree of amplification ≥2.0 according to the results of in situ hybridization (ISH);
  6. Patients with stable metastatic brain foci for at least 4-6 weeks (according to MRI);
  7. Patients with HER2+ inoperable locally advanced or metastatic breast cancer who previously received taxanes and trastuzumab;
  8. 0-1 status;
  9. of more than 6 months.

Exclusion criteria

Exclusion Criteria:

  1. T-DM1 therapy in the medical history;
  2. diseases in the medical history or treatment of exacerbations during the last three months;
  3. Uncontrolled and/or carcinomatous meningitis, causing neurological symptoms;
  4. Primary multiple malignant tumors: other malignant neoplasms requiring active treatment;
  5. Acute myocardial infarction, acute cerebrovascular accident, uncorrectable coagulopathy, decompensated concomitant pathology, infectious diseases in the active phase, status > 2;
  6. Pregnancy, lactation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Prospective group: STR + trastuzumab emtansine 24 hours after the STR

    STR + trastuzumab emtansine. Patients included in the study will will undergo SRT for up to 2 cycles, depending on the location of the irradiated focus, followed by administration of trastuzumab emtansine at a dose of 3.6 mcg/kg once every 3 weeks, up to 4 total cycles. Targeted therapy with trastuzumab emtansine should commence 24 hours after the completion of SRT.

    Drug: Trastuzumab emtansine

  • No intervention
    Retrospective group: STR + trastuzumab emtansine > 24 hours after the STR

    Patients with oligometastatic HER2+ breast cancer who were treated with trastuzumab-emtansine and who had a history of SRT. Retrospectively, using CT and MRI data, the dynamics of the process will be evaluated according to the RECIST 1.1. Based on the data of the medical documentation of patients, the main statistical indicators will be calculated.

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Objective response rate is defined as the proportion of participants who have a confirmed CR or PR, as determined by investigator assessment, per RECIST 1.1

    Time frame: 3 month

Secondary outcomes

  1. Progression free survival (PFS)

    Progression free survival (PFS) is defined as the time from the start of study treatment until the disease progression or death.

    Time frame: 6 month

  2. Toxicity profile

    The assessment of adverse events will be carried out according to the STS AE v.5.0 system.

    Time frame: 3 month

  3. Second co-primary outcome measure is quality of life

    of Cancer (EORTC) Quality of Life Questionnaire for Cancer patients with 30 items (QLQ-C30) sum score

    Time frame: 3 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Sep 2025, 38 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 38 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2024
First posted
Mar 8, 2024
StartActual
Jul 1, 2022
Primary completionEst.
Sep 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06299852
Lead sponsor
N.N. Petrov National Medical Research Center of Oncology
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Jul 1, 2022
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Mar 8, 2024

Study contacts

Tatiana Semiglazova, DSc Med., Prof.
Contact
tsemiglazova@mail.ru
+79219468072
Tatiana Kudryashova
Contact
tatyana-kudryashova-98@mail.ru
+79632165730

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ado-Trastuzumab Emtansine

Start the discussion